9.32
0.19 (2.08%)
| Previous Close | 9.13 |
| Open | 9.00 |
| Volume | 60,142 |
| Avg. Volume (3M) | 72,516 |
| Market Cap | 84,313,552 |
| Price / Earnings (TTM) | 10.47 |
| Price / Sales | 390.27 |
| Price / Book | 1.91 |
| 52 Weeks Range | |
| Earnings Date | 12 Mar 2026 |
| Diluted EPS (TTM) | -7.95 |
| Total Debt/Equity (MRQ) | 177.45% |
| Current Ratio (MRQ) | 2.11 |
| Operating Cash Flow (TTM) | -86.46 M |
| Levered Free Cash Flow (TTM) | -59.84 M |
| Return on Assets (TTM) | -28.22% |
| Return on Equity (TTM) | -1,556.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Seres Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -4.0 |
| Average | 0.00 |
|
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 13.01% |
| % Held by Institutions | 35.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Flagship Pioneering, Llc | 31 Dec 2025 | 1,155,850 |
| Lion Point Capital, Lp | 31 Dec 2025 | 31,570 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |